응급실을 방문한 광범위베타락탐분해효소 양성 대장균 요로감염 환자의 임상적 특징 및 위험인자
Clinical characteristics of children who visited the emergency department with extended-spectrum beta-lactamase-producing Escherichia coli urinary tract infection and its risk factors
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To identify the differences in features between children with urinary tract infection (UTI) caused by extended-spectrum beta-lactamases (ESBL)-positive and -negative Escherichia coli, and analyze risk factors for the former infection. Methods: We reviewed medical records of children younger than 36 months with E. coli UTI who visited the emergency department from January 2012 through January 2019. Differences in variables regarding clinical, laboratory, and microbiologic (i.e., ESBL-positive E. coli on urine culture) features, and outcomes between the ESBL-positive and -negative groups were identified. Factors associated with ESBL-positive E. coli infection were analyzed by logistic regression. Results: The children were classified into the ESBL-positive (n = 151) and -negative (n = 40) groups. The former group showed higher frequency of prior UTI (P = 0.038) without other differences between the groups. The median counts of white blood cells, absolute neutrophils, and absolute lymphocytes were higher in the ESBL-positive group than in the other group (P = 0.009, 0.022, and 0.027, respectively). The former group showed longer median hospital length of stay (11.0 days [interquartile range, 8.9-12.0] vs. 6.0 [5.0-7.0]; P < 0.001), and more frequent recurrence per child (3.0 [2.5-3.0] vs. 1.0 [1.0- 1.8]; P = 0.047) and presence of vesicoureteral reflux (27.5% vs. 13.2%; P = 0.001). Logistic regression showed leukocytosis (odds ratio, 12.85; 95% confidence interval, 1.04-157.69) and vesicoureteral reflux (4.00; 1.19-13.43) as the factors for ESBL-positive E. coli infection. Conclusion: The ESBL-positive group showed significantly higher leukocyte count and rate of vesicoureteral reflux than the ESBL-negative group. For children with these features, empirical antibiotics should be chosen in consideration of the resistant bacteria.
Abstract
Purpose: To identify the differences in features between children with urinary tract infection (UTI) caused by extended-spectrum beta-lactamases (ESBL)-positive and -negative Escherichia coli, and analyze risk factors for the former infection. Methods: We reviewed medical records of children younger than 36 months with E. coli UTI who visited the emergency department from January 2012 through January 2019. Differences in variables regarding clinical, laboratory, and microbiologic (i.e., ESBL-positive E. coli on urine culture) features, and outcomes between the ESBL-positive and -negative groups were identified. Factors associated with ESBL-positive E. coli infection were analyzed by logistic regression. Results: The children were classified into the ESBL-positive (n = 151) and -negative (n = 40) groups. The former group showed higher frequency of prior UTI (P = 0.038) without other differences between the groups. The median counts of white blood cells, absolute neutrophils, and absolute lymphocytes were higher in the ESBL-positive group than in the other group (P = 0.009, 0.022, and 0.027, respectively). The former group showed longer median hospital length of stay (11.0 days [interquartile range, 8.9-12.0] vs. 6.0 [5.0-7.0]; P < 0.001), and more frequent recurrence per child (3.0 [2.5-3.0] vs. 1.0 [1.0- 1.8]; P = 0.047) and presence of vesicoureteral reflux (27.5% vs. 13.2%; P = 0.001). Logistic regression showed leukocytosis (odds ratio, 12.85; 95% confidence interval, 1.04-157.69) and vesicoureteral reflux (4.00; 1.19-13.43) as the factors for ESBL-positive E. coli infection. Conclusion: The ESBL-positive group showed significantly higher leukocyte count and rate of vesicoureteral reflux than the ESBL-negative group. For children with these features, empirical antibiotics should be chosen in consideration of the resistant bacteria.
참고문헌 (27)
- Shaikh N, "Prevalence of urinary tract infection in childhood : a meta-analysis", Pediatr Infect Dis J, 27, pp.302~308 (2008)
- Schmidt B, "Work-up of pediatric urinary tract infection", Urol Clin North Am, 42, pp.519~526 (2015)
- Nuutinen M, "Clinical guidelines and hospital discharges of children with acute urinary tract infections", Pediatr Nephrol, 13, pp.45~49 (1999)
- Newman TB, "The new American Academy of Pediatrics urinary tract infection guideline", Pediatrics, 128, pp.572~575 (2011)
- Okarska-Napierała M, "Urinary tract infection in children : Diagnosis, treatment, imaging-comparison of current guidelines", J Pediatr Urol, 13, pp.567~573 (2017)
- Bryce A, "Global prevalence of antibiotic resistance in paediatric urinary tract infections caused by Escherichia coli and association with routine use of antibiotics in primary care : systematic review and meta-analysis", BMJ, 352, pp.i939~ (2016)
- Sefton AM, "The impact of resistance on the management of urinary tract infections", Int J Antimicrob Agents, 16, pp.489~491 (2000)
- Mazzariol A, "Multi-drug-resistant Gram-negative bacteria causing urinary tract infections : a review", J Chemother, 29(Suppl 1), pp.2~9 (2017)
- 유영명, "An Epidemiologic Study on Hosts and Pathogens of Urinary Tract Infection in Urban Children of Korea (2012–2017)", Childhood Kidney Diseases, 23(1), pp.29~35 (2019), 대한소아신장학회[DOI]
- 이정원, "지역사회 획득 소아 요로검염에서 Extended-Spectrum b-Lactamase 생성 Escherichia coli의 발생과 위험인자", Childhood Kidney Diseases, 8(2), pp.214~222 (2004), 대한소아신장학회
- Uyar Aksu N, "Childhood urinary tract infection caused by extended-spectrum β-lactamase-producing bacteria : Risk factors and empiric therapy", Pediatr Int, 59, pp.176~180 (2017)
- Lee H, "Risk factors of urinary tract infection caused by extended spectrum β-lactamase-producing Escherichia coli in emergency department", Am J Emerg Med, 36, pp.1608~1612 (2018)
- Melzer M, "Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL)producing E. coli compared to non-ESBL producing E. coli", J Infect, 55, pp.254~259 (2007)
- Ray S, "Association of high mortality with extended-spectrum β-lactamase(ESBL)positive cultures in community acquired infections", J Crit Care, 44, pp.255~260 (2018)
- Ramphal R, "Extended-spectrum β-lactamases and clinical outcomes : current data", Clin Infect Dis, 42(Suppl), pp.S164~S172 (2006)
- Greenhouse I, "Long-term outcomes of inappropriate antibiotic therapy for upper urinary tract infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae : a retrospective cohort study", Diagn Microbiol Infect Dis, 89, pp.222~229 (2017)
- Toubiana J, "Community-onset extended-spectrum β-lactamase-producing Enterobacteriaceae invasive infections in children in a university hospital in France", Medicine(Baltimore), 95, pp.e3163~ (2016)
- Lukac PJ, "Extended-spectrum βlactamase-producing Enterobacteriaceae in children : old foe, emerging threat", Clin Infect Dis, 60, pp.1389~1397 (2015)
- Rodríguez-Baño J, "Clinical significance of extended-spectrum β-lactamases", Expert Rev Anti Infect Ther, 6, pp.671~683 (2008)
- Ahn ST, "Does urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli show same antibiotic resistance when it recurs?", J Infect Chemother, 25, pp.498~502 (2019)
- 박철, "발열성 소아 요로감염에서 Extended-Spectrum β- Lactamase 생성 Escherichia coli의 임상적 의의", Childhood Kidney Diseases, 16(1), pp.38~45 (2012), 대한소아신장학회[DOI]
- Coque TM, "Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe", Euro Surveill, 13, pp.19044~ (2008)
- Polat M, "Once-daily intramuscular amikacin for outpatient treatment of lower urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli in children", Infect Drug Resist, 10, pp.393~399 (2017)
- Esteve-Palau E, "Clinical and economic impact of urinary tract infections caused by ESBL-producing Escherichia coli requiring hospitalization : a matched cohort study", J Infect, 71, pp.667~674 (2015)
- Concia E, "Actual role of older oral antibiotics in the treatment of resistant urinary tract infections(UTIs)", J Chemother, 29(Suppl 1), pp.1~ (2017)
- Sethaphanich N, "Pediatric extended spectrum β-lactamase infection : community-acquired infection and treatment options", Pediatr Int, 58, pp.338~346 (2016)
- Seo YB, "Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli", BMC Infect Dis, 17, pp.404~ (2017)